China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class ASZSE: 300294

China Resources Boya Bio-pharmaceutical Group: Revenue up, profit down YTD, cash flow pressured, Boya Xinhe deconsolidated

· Issued by China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

Q3 2025 revenue grew 33.43% year-over-year, driven by Green Cross consolidation, but YTD net profit fell 16.90% due to higher costs and asset write-downs. Cash flow from operations dropped 90.05%, and Boya Xinhe was deconsolidated after an 80% equity sale.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

All China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A news releases